$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

소시호탕 systemic review 및 KCD 코드 대조
Systemic review of Xiaochaihutang and its correlation with KCD 원문보기

大韓韓醫學方劑學會誌 = Herbal formula science, v.28 no.1, 2020년, pp.117 - 135  

이지호 (동국대학교 한의과대학 방제학교실) ,  박선동 (동국대학교 한의과대학 방제학교실) ,  김영우 (동국대학교 한의과대학 방제학교실)

Abstract AI-Helper 아이콘AI-Helper

Objectives : Xiaochaihutang(小柴胡湯) is a famous herbal prescription in the Traditional Korean Medicine, and its components include Bupleuri Radix(柴胡), Scutellariae Radix(黃芩), Ginseng Radix(人蔘), Pinelliae Tuber(半夏), Glycyrrhizae Radix et Rhizoma(甘草), Zingiberis Rhizoma Crudus(生薑), Zizyphi Fructus(大棗). ...

주제어

표/그림 (3)

AI 본문요약
AI-Helper 아이콘 AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

문제 정의

  • 본 연구는 해외 포털 사이트 검색을 통해 지금까지 이루어진 소시호탕에 대한 연구 성과들을 확인하고, 기존 전통적으로 인식되어온 六經辨證이나 辨證論治, 나아가 證候的 진단에 의존한 처방인식체계를 벗어나 국가적 표준화된 기준에 접근하는 처방인식방법이 필요할 것으로 판단하여 이와 연관되는 KCD 코드를 대조하여 소시호탕의 임상적 활용 분야 및 새로운 가능성을 확인해보았다. 이를 바탕으로 향후 소시호탕에 대한 기초 및 임상 연구의 방향성뿐만 아니라, 임상적 활용에 대한 근거를 제시하고자 한다.
  • 소시호탕은 간질환에 특이적일 뿐 아니라 면역조절 능력(immunomodulatory activity)을 바탕으로 미생물 감염에 의한 국소 및 전신적 증상 완화 효과, 항암 효과, 항염효과가 있는 것으로 확인되었다. 본 연구에서 신체분류별 KCD로 감염에 분류된 9건의 논문은 만성 간염, 콕사키 바이러스(Coxsackie virus), 엡스타인 바 바이러스(Epstein-Barr Virus) 감염증에 대한 소시호탕의 항바이러스 효능을 연구하였다. 인체는 바이러스 감염 발생 시 우선적으로 선천 면역계 활성을 통해 바이러스의 세포내 침습과 복제를 억제한다63) .
  • 본 연구는 해외 포털 사이트 검색을 통해 지금까지 이루어진 소시호탕에 대한 연구 성과들을 확인하고, 기존 전통적으로 인식되어온 六經辨證이나 辨證論治, 나아가 證候的 진단에 의존한 처방인식체계를 벗어나 국가적 표준화된 기준에 접근하는 처방인식방법이 필요할 것으로 판단하여 이와 연관되는 KCD 코드를 대조하여 소시호탕의 임상적 활용 분야 및 새로운 가능성을 확인해보았다. 이를 바탕으로 향후 소시호탕에 대한 기초 및 임상 연구의 방향성뿐만 아니라, 임상적 활용에 대한 근거를 제시하고자 한다.
본문요약 정보가 도움이 되었나요?

질의응답

핵심어 질문 논문에서 추출한 답변
소시호탕은 어떤 처방인가?  소시호탕(小柴胡湯)은 <상한론>의 辨太陽病脈證幷 治上에서 출전한 고방(古方)으로 <방제학>에서 和解 劑 중 和解少陽劑로 분류된 半表半裏證을 다스리는 처방이다1,2) . <상한론>에서 소시호탕의 적응증으로는 寒熱往來, 胸脇苦滿, 不欲飮食, 心煩喜嘔 등의 傷寒 少陽證이 제시되었으며, 이외에도 傷寒에 의한 부인의 熱入血室 등 다양한 증후에 적용됨을 기록으로 전해오고 있다.
<상한론>에서 소시호탕의 적응증으로는 무엇이 제시되었는가?  소시호탕(小柴胡湯)은 <상한론>의 辨太陽病脈證幷 治上에서 출전한 고방(古方)으로 <방제학>에서 和解 劑 중 和解少陽劑로 분류된 半表半裏證을 다스리는 처방이다1,2) . <상한론>에서 소시호탕의 적응증으로는 寒熱往來, 胸脇苦滿, 不欲飮食, 心煩喜嘔 등의 傷寒 少陽證이 제시되었으며, 이외에도 傷寒에 의한 부인의 熱入血室 등 다양한 증후에 적용됨을 기록으로 전해오고 있다. 和解治法의 기본방인 소시호탕은 증후의 虛實에 따라 시호계지건강탕(柴胡桂枝乾薑湯), 대시호탕(大柴胡湯) 등으로 응용되며, 후세방에서 소요산(逍遙散), 보중익기탕(補中益氣湯)의 근간이 될 만큼 임상적으로 중요한 처방이다3) .
소시호탕의 구성중 柴胡은 어떤 효능을 지녔는가? 소시호탕은 柴胡, 黃芩, 人蔘, 半夏, 甘草, 生薑, 大棗로 구성된다. 그 중 柴胡는 少陽病을 다스리는 主藥으로 解表退熱과 疏肝解鬱의 효능을 통해 少陽의 邪氣를 발산시키고 表熱을 제거하는 君藥이다. 黃芩 은 苦寒한 性味를 바탕으로 少陽의 邪氣에 의한 裏熱 을 제거하는 臣藥이다.
질의응답 정보가 도움이 되었나요?

참고문헌 (85)

  1. Moon JJ, Ahn GS, Kim SH, Park JH, Kim DH, Choi DY, et al. ShangHanLunJeongHae, Seoul: Publication HanEuiMunHwaSa:214-217, 2010. 

  2. Kook YB, Kim SC, Park SD, Park SK, Seo BI, Seo YB, Shin SS, Lee SI, Lee JC, Lee KH, Jeong JG, Ju YS, Choi HY, Formula Study. Seoul: Younglimsa:143-146, 2006. 

  3. Shin JY. Explanation of Formulas and Medicinals Compilation. Seoul: Publication Seongbosa, 1988. 

  4. Herbology Editorial Committee of Korean Medicine schools. Boncho-hak. Seoul : Publication Younglimsa:171, 186, 216, 485, 573, 584, 586, 2004. 

  5. Lee IS. Korean Standard Classification of Disease Volume 1, Seoul : Statistics Korea: 5-20, 2015. 

  6. Baik YS. A Study on the Complex Efficacy of Sosihotang. J Korean Medical Classics 27(2):137-152, 2014. 

  7. Back SY. Study on mediation-medicine in Sanhanlun. J Korean Medical Classics 14(2):191-214, 2001. 

  8. Kim SU, Jung HJ. A Research of Definition and Treatment of Dizziness in the Books on Cold Damage. The Journal of the Society of Korean Medicine Diagnostics 18(3):149-174, 2014. 

  9. Zhang K, Wang Z, Pan X, Yang J, Wu C. Antidepressant-like effects of Xiaochaihutang in perimenopausal mice. J Ethnopharmacol 248:112318, 2020. 

  10. Zhang K, He M, Su D, Pan X, Li Y, Zhang H, Yang J, Wu C. Quantitative proteomics reveal antidepressant potential protein targets of xiaochaihutang in corticosterone induced model of depression. J Ethnopharmacol 231:438-445, 2019. 

  11. Hu R, Jia WY, Xu SF, Zhu ZW, Xiao Z, Yu SY, Li J. Xiaochaihutang Inhibits the Activation of Hepatic Stellate Cell Line T6 Through the Nrf2 Pathway. Front Pharmacol 9:1516, 2019. 

  12. Li J, Hu R, Xu S, Li Y, Qin Y, Wu Q, Xiao Z. Xiaochaihutang attenuates liver fibrosis by activation of Nrf2 pathway in rats. Biomed Pharmacother 96:847-853, 2017. 

  13. Ma J, Wang F, Yang J, Dong Y, Su G, Zhang K, Pan X, Ma P, Zhou T, Wu C. Xiaochaihutang attenuates depressive/anxiety- like behaviors of social isolation-reared mice by regulating monoaminergic system, neurogenesis and BDNF expression. J Ethnopharmacol 208:94-104, 2017. 

  14. Zhao J, Liu L, Zhang Y, Wan Y, Hong Z. THE HERBAL MIXTURE XIAO-CHAI-HU TANG (XCHT) INDUCES APOPTOSIS OF HUMAN HEPATOCELLULAR CARCINOMA HUH7 CELLS IN VITRO AND IN VIVO. Afr J Tradit Complement Altern Med 14(3):231-241, 2017. 

  15. Zhang K, Yang J, Wang F, Pan X, Liu J, Wang L, Su G, Ma J, Dong Y, Xiong Z, Wu C. Antidepressant-like effects of Xiaochaihutang in a neuroendocrine mouse model of anxiety/depression. J Ethnopharmacol 194:674-683, 2016. 

  16. Ma J, Wu CF, Wang F, Yang JY, Dong YX, Su GY, Zhang K, Wang ZQ, Xu LW, Pan X, Zhou TS, Ma P, Song SJ. Neurological mechanism of Xiaochaihutang's antidepressant-like effects to socially isolated adult rats. J Pharm Pharmacol 68(10):1340-9, 2016. 

  17. Xiong Z, Yang J, Huang Y, Zhang K, Bo Y, Lu X, Su G, Ma J, Yang J, Zhao L, Wu C. Serum metabonomics study of anti- depressive effect of Xiao-Chai-Hu-Tang on rat model of chronic unpredictable mild stress. J Chromatogr B Analyt Technol Biomed Life Sci 1029-1030:28-35, 2016. 

  18. Jeon WY, Shin HK, Shin IS, Kim SK, Lee MY. Soshiho-tang water extract inhibits ovalbumin-induced airway inflammation via the regulation of heme oxygenase-1. BMC Complement Altern Med 18;15:329, 2015. 

  19. Nishizaki D, Iwahashi H. Baicalin inhibits the fenton reaction by enhancing electron transfer from Fe (2+) to dissolved oxygen. Am J Chin Med 43(1):87-101, 2015. 

  20. Chen YW, Tsai MY, Pan HB, Tseng HH, Hung YT, Chou CP. Gadoxetic acid- enhanced MRI and sonoelastography: non- invasive assessments of chemoprevention of liver fibrosis in thioacetamide-induced rats with Sho-Saiko-To. PLoS One 9(12):e114756, 2014. 

  21. Takahashi Y, Soejima Y, Kumagai A, Watanabe M, Uozaki H, Fukusato T. Japanese herbal medicines shosaikoto, inchinkoto, and juzentaihoto inhibit high-fat diet-induced nonalcoholic steatohepatitis in db/db mice. Pathol Int 64(10):490-8, 2014. 

  22. Takahashi Y, Soejima Y, Kumagai A, Watanabe M, Uozaki H, Fukusato T. Inhibitory effects of Japanese herbal medicines sho- saiko-to and juzen-taiho-to on nonalcoholic steatohepatitis in mice. PLoS One 9(1):e87279, 2014. 

  23. Su GY, Yang JY, Wang F, Ma J, Zhang K, Dong YX, Song SJ, Lu XM, Wu CF. Antidepressant-like effects of Xiaochaihutang in a rat model of chronic unpredictable mild stress. J Ethnopharmacol 152(1):217-26, 2014. 

  24. Su GY, Yang JY, Wang F, Xiong ZL, Hou Y, Zhang K, Song C, Ma J, Song SJ, Teng HF, Wu CF. Xiaochaihutang prevents depressive- like behaviour in rodents by enhancing the serotonergic system. J Pharm Pharmacol 66(6):823-34, 2014. 

  25. Lee JJ, Kim T, Cho WK, Ma JY. Antithrombotic and antiplatelet activities of Soshiho-tang extract. BMC Complement Altern Med 13:137, 2013. 

  26. Zhou YX, Qiu YQ, Xu LQ, Guo J, Li LJ. Xiao-Chai-Hu Tang in treating model mice with D-galactosamine-induced liver injury. Afr J Tradit Complement Altern Med 9(3):405-11, 2012. 

  27. Deng G, Kurtz RC, Vickers A, Lau N, Yeung KS, Shia J, Cassileth B. A single arm phase II study of a Far-Eastern traditional herbal formulation (sho-sai-ko-to or xiao-chai-hu-tang) in chronic hepatitis C patients. J Ethnopharmacol 136(1):83-7, 2011. 

  28. Kang H, Choi TW, Ahn KS, Lee JY, Ham IH, Choi HY, Shim ES, Sohn NW. Upregulation of interferon-gamma and interleukin-4, Th cell-derived cytokines by So-Shi-Ho-Tang (Sho-Saiko-To) occurs at the level of antigen presenting cells, but not CD4 T cells. J Ethnopharmacol 123(1):6-14, 2009. 

  29. Kasai A, Hiramatsu N, Hayakawa K, Yao J, Kitamura M. Blockade of the dioxin pathway by herbal medicine Formula Bupleuri Minor: identification of active entities for suppression of AhR activation. Biol Pharm Bull 31(5):838-46, 2008. 

  30. Chang JS, Wang KC, Liu HW, Chen MC, Chiang LC, Lin CC. Sho-saiko-to (Xiao-Chai-Hu-Tang) and crude saikosaponins inhibit hepatitis B virus in a stable HBVproducing cell line. Am J Chin Med 35(2):341-51, 2007. 

  31. Cheng PW, Ng LT, Lin CC. Xiao chai hu tang inhibits CVB1 virus infection of CCFS-1 cells through the induction of Type I interferon expression. Int Immunopharmacol 6(6):1003-12, 2006. 

  32. Rino Y, Tarao K, Morinaga S, Ohkawa S, Miyakawa K, Hirokawa S, Masaki T, Tarao N, Yukawa N, Saeki H, Takanashi Y, Imada T. Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis. Anticancer Res 26(3B):2221-6, 2006. 

  33. Makino T, Tsubouchi R, Murakami K, Haneda M, Yoshino M. Generation of reactive oxygen species and induction of apoptosis of HL60 cells by ingredients of traditional herbal medicine, Sho-saiko-to. Basic Clin Pharmacol Toxicol 98(4):401-5, 2006. 

  34. Zhu K, Fukasawa I, Furuno M, Inaba F, Yamazaki T, Kamemori T, Kousaka N, Ota Y, Hayashi M, Maehama T, Inaba N. Inhibitory effects of herbal drugs on the growth of human ovarian cancer cell lines through the induction of apoptosis. Gynecol Oncol. 97(2):405-9, 2005. 

  35. Ohtake N, Yamamoto M, Takeda S, Aburada M, Ishige A, Watanabe K, Inoue M. The herbal medicine Sho-saiko-to selectively inhibits CD8+ T-cell proliferation. Eur J Pharmacol 507(1-3):301-10, 2005. 

  36. Chen MH, Chen JC, Tsai CC, Wang WC, Chang DC, Tu DG, Hsieh HY. The role of TGF-beta 1 and cytokines in the modulation of liver fibrosis by Sho-saiko-to in rat's bile duct ligated model. J Ethnopharmacol 97(1):7-13, 2005. 

  37. Sakaguchi S, Furusawa S, Iizuka Y. Preventive effects of a traditional Chinese medicine (Sho-saiko-to) on septic shock symptoms; approached from heme metabolic disorders in endotoxemia. Biol Pharm Bull 28(1):165-8, 2005. 

  38. Kaneko T, Chiba H, Horie N, Hashimoto K, Satoh K, Kusama K, Sakagami H. Effect of two different groups of Chinese medicines on nitric oxide production by mouse macrophage-like cells. In Vivo 18(6):771-8, 2004. 

  39. Sakaguchi S, Furusawa S. Preventive effects of a traditional Chinese medicine (Sho-saiko-to) on endotoxin-induced cytotoxicity and tumor necrosis factor-alpha production in J774A.1 Cells. Biol Pharm Bull 27(9): 1468-70, 2004. 

  40. Chen MH, Chen JC, Tsai CC, Wang WC, Chang DC, Lin CC, Hsieh HY. Sho-saiko-to prevents liver fibrosis induced by bile duct ligation in rats. Am J Chin Med 32(2):195-207, 2004. 

  41. Sakaida I, Hironaka K, Kimura T, Terai S, Yamasaki T, Okita K. Herbal medicine Sho-saiko-to (TJ-9) increases expression matrix metalloproteinases (MMPs) with reduced expression of tissue inhibitor of metalloproteinases (TIMPs) in rat stellate cell. Life Sci 74(18):2251-63, 2004. 

  42. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Namisaki T, Yamazaki M, Tsujinoue H, Imazu H, Fukui H. Extracellular matrix remodeling may predominate over hepatocyte injury in hepatocellular carcinoma development. Oncol Rep 10(4): 957-62, 2003. 

  43. Kusunose M, Qiu B, Cui T, Hamada A, Yoshioka S, Ono M, Miyamura M, Kyotani S, Nishioka Y. Effect of Sho-saiko-to extract on hepatic inflammation and fibrosis in dimethylnitrosamine induced liver injury rats. Oncol Rep 25(11):1417-21, 2002. 

  44. Ohtake N, Nakai Y, Yamamoto M, Ishige A, Sasaki H, Fukuda K, Hayashi S, Hayakawa S. The herbal medicine Shosaiko-to exerts different modulating effects on lung local immune responses among mouse strains. Int Immunopharmacol 2(2-3):357-66, 2002. 

  45. Matsumoto T, Shibata T. The ex vivo effect of the herbal medicine sho-saiko-to on histamine release from rat mast cells. Eur Arch Otorhinolaryngol 255(7):359-64, 1998. 

  46. Mizushima Y, Kashii T, Tokimitsu Y, Kobayashi M. Cytotoxic effect of herbal medicine sho-saiko-to on human lung-cancer celllines in-vitro. Oncol Rep 2(1):91-4, 1995. 

  47. Kaneko M, Kawakita T, Tauchi Y, Saito Y, Suzuki A, Nomoto K. Augmentation of NK activity after oral administration of a traditional Chinese medicine, xiao-chai-hutang (shosaiko-to). Immunopharmacol Immunotoxicol 16(1):41-53, 1994. 

  48. Tauchi Y, Yamada A, Kawakita T, Saito Y, Suzuki A, Yoshikai Y, Nomoto K. Enhancement of immunoglobulin A production in Peyer's patches by oral administration of a traditional Chinese medicine, xiao-chai-hu-tang (Shosaiko-to). Immunopharmacol Immunotoxicol 15(2-3):251-72, 1993. 

  49. Matsuura K, Kawakita T, Nakai S, Saito Y, Suzuki A, Nomoto K. Role of B-lymphocytes in the immunopharmacological effects of a traditional Chinese medicine, xiao-chai-hutang (shosaiko-to). Int J Immunopharmacol 15(2):237-43, 1993. 

  50. Furukawa M, Sakashita H, Kamide M, Umeda R. Inhibitory effects of kampo medicine on Epstein-Barr virus antigen induction by tumor promoter. Auris Nasus Larynx 17(1):49-54, 1990. 

  51. Yonekura K, Kawakita T, Mitsuyama M, Miura O, Yumioka E, Suzuki A, Nomoto K. Induction of colony-stimulating factor(s) after administration of a traditional Chinese medicine, xiao-chai-hu-tang (Japanese name: shosaiko-to). Immunopharmacol Immunotoxicol 12(4):647-67, 1990 

  52. Kawakita T, Nakai S, Kumazawa Y, Miura O, Yumioka E, Nomoto K. Induction of interferon after administration of a traditional Chinese medicine, xiao-chai-hu- tang (shosaiko-to). Int J Immunopharmacol 12(5):515-21, 1990 

  53. Lee KS. Hepatic fibrogenesis. Korean J Gastroenterol 48(5):297-305, 2006. 

  54. La Vecchia C, Negri E, Cavalieri d'Oro L, Franceschi S. Liver cirrhosis and the risk of primary liver cancer. Eur J Cancer Prev 7(4):315-20, 1998. 

  55. Chen Z. The Necessity and inevitability of the Combination of eastern and Western medicine as proved by the treatment of Chronic hepatitis B. International symposium on East-West Medicine: 125-39, 1994. 

  56. Lok AS, Wu P-C, Lai C-L, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 102:2091-7, 1992. 

  57. Chan HL, Chan CK, Hui AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology 146:1240-8, 2014. 

  58. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140(5):346-55, 2004. 

  59. Sael Casas-Grajales, Pablo Muriel. Antioxidants in liver health. World J Gastrointest Pharmacol Ther 6(3): 59-72, 2015. 

  60. Lin CC, Shieh DE. The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am J Chin Med 24(1):31-6, 1996. 

  61. Shen YC, Chiou WF, Chou YC, Chen CF. Mechanisms in mediating the anti-inflammatory effects of baicalin and baicalein in human leukocytes. Eur J Pharmacol 465(1-2):171-81, 2003. 

  62. Kubo M, Matsuda H, Tanaka M, Kimura Y, Okuda H, Higashino M, Tani T, Namba K, Arichi S. Studies on Scutellariae radix. VII. Anti-arthritic and anti-inflammatory actions of methanolic extract and flavonoid components from Scutellariae radix. Chem Pharm Bull (Tokyo) 32(7):2724-9, 1984. 

  63. S Koyama, KJ Ishii, C Coban, S Akira. Innate immune response to viral infection. Cytokine 43(3): 336-341, 2008. 

  64. Levy DE, Marie IJ, Durbin JE. Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol 1(6):476-86, 2011. 

  65. Oludare A. Odumade, Kristin A. Hogquist, Henry H. Balfour, Jr. Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections. Clin Microbiol Rev 24(1):193-209, 2011. 

  66. Roberta Caorsi, Antonella Buoncompagni, Francesca Minoia, Paolo Picco, Sara Signa, Silvia Federici, Martina Finetti, Alberto Martini, Marco Gattorno. Chronic active EBV infection mimicking periodic fever syndromes: a new challenge for the paediatrician. Pediatric Rheumatology 12(Suppl 1):168, 2014. 

  67. LEE SI, Jeong JG. A Study on the Diversity of Shanghan Concept in Gangpyeong-Sanghanlun. J Korean Medical Classics 28(1):97-110, 2015. 

  68. Richard S. Hotchkiss, Lyle L. Moldawer, Steven M. Opal, Konrad Reinhart, Isaiah R. Turnbull, Jean-Louis Vincent. Sepsis and septic shock. Nat Rev Dis Primers 2: 16045, 2016. 

  69. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 328(20):1471-7, 1993. 

  70. Titheradge MA. Nitric oxide in septic shock. Biochimica et Biophysica Acta (BBA)-Bioenergetics 1411(2-3):437-455, 1999. 

  71. Park SY, Hong SB. Treatment Guidelines of Severe Sepsis and Septic Shock. J Neurocrit Care 8(1):9-15, 2015. 

  72. Chen D, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 541:321-330, 2017. 

  73. Murray I, Patterson A, Perdew G. Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer 14:801-814, 2014. 

  74. Feng S, Cao Z, Wang X. Role of aryl hydrocarbon receptor in cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1836(2):197-210, 2013. 

  75. Liu Z, Zhang F, Han L, Bao G, He X, Xu Z. AhR expression is increased in hepatocellular carcinoma. Journal of molecular histology 44(4):455-461, 2013. 

  76. Brown JM, Wilson TM, Metcalfe DD. The mast cell and allergic diseases: role in pathogenesis and implications for therapy. Clinical & Experimental Allergy 38(1):4-18, 2008. 

  77. Haase J, Brown E. Integrating the monoamine, neurotrophin and cytokine hypotheses of depression-a central role for the serotonin transporter? Pharmacology & therapeutics 147:1-11, 2015. 

  78. Dean J, Keshavan M. The neurobiology of depression: An integrated view. Asian journal of psychiatry 27:101-111, 2017. 

  79. L Neto F, Borges G, Torres-Sanchez S, A Mico J, Berrocoso E. Neurotrophins role in depression neurobiology: a review of basic and clinical evidence. Current neuropharmacology 9(4):530-552, 2011. 

  80. Park SC, Sung SH, Han KM, Won ES, Lee HY. Evidence-Based Korean Pharmacological Treatment Guideline for Depression, Revised Edition (I) : Initial Choice of Antidepressant Treatment. J Korean Neuropsychiatr Assoc 52:253-262, 2013. 

  81. Kang HW, Jang HH, Kang IS, Moon HC, Hwang YJ, Lyu YS. A Study on The Oriental-medical Understanding of Depression. Journal of oriental neuropsychiatry 12(2):1-15, 2001. 

  82. Korea Institute of Korean Medicine. Korean Medicine Clinical Practice Guideline-Depression. Daejeon, 2016. 

  83. Herbology Editorial Committee of Korean Medicine schools. Boncho-hak. Seoul : Publication Younglimsa:186, 2004. 

  84. Hong SY, Park SD. The effect of Bupleurum falcatum L. on the catecholamines of depression rat model. The Korea journal of herbology 18(4):245-253, 2003. 

  85. Li YH, Kim DH, Lee TH. Effect of Mixture extracted from Bupleuri Radix and Physalidis Herba on the LPS-induced depression in Rats. The Korea journal of herbology 30(3): 69-76, 2015. 

저자의 다른 논문 :

섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로